Login to Your Account



QuatRx Boosts Pipeline Work With $44M Series E Financing

By Jennifer Boggs


Wednesday, May 23, 2007
In its largest financing round to date, QuatRx Pharmaceuticals Co. brought in $44 million in a Series E round to support ongoing clinical development of two endocrine programs, including a Phase III-stage selective estrogen receptor modulator for vaginal atrophy, and an early clinical-stage lipid-lowering compound. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription